Global Research Antibodies and Reagents Market

Monoclonal antibodies (MABS) refer to laboratory-produced proteins intended to boost your immune system. Treatments for monoclonal antibodies are often administered as IV solutions, frequently in an infusion center. Antibodies are a component of your immune system.To kill them, they seek out the antigens (foreign substances) and adhere to them. The main types of sources of monoclonal antibodies (MABS) are murine, chimeric, humanized, and human. A murine antibody has two types of chains, one of which is from a mouse and the other from a human. The pre-stem -o- in the INN of a murine antibody is used to identify it.It is used in anti-cancer, immunological, anti-infective monoclonal antibodies (MAbs), neuropharmacological, cardiovascular, cerebrovascular, and other applications and implemented in various sectors such as hospitals, private clinics, and research institutes. The monoclonal antibodies (MABS) market research report is one of a series of new reports from The Business Research Company that provides monoclonal antibodies (MABS) market statistics, such as industry global market size, regional shares, competitors with a monoclonal antibodies (MABS) market share, detailed monoclonal antibodies (MABS) market segments, market trends and opportunities, and any additional data you may require to thrive in the monoclonal antibodies (MABS) industry.This monoclonal antibody (MABS) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global monoclonal antibodies (mabs) market grew from $188.18 billion in 2022 to $209.98 billion in 2023 at a compound annual growth rate (CAGR) of 11.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The monoclonal antibodies (mabs) market is expected to grow from $330.35 billion in 2027 at a CAGR of 12.0%. The increasing prevalence of cost-efficient biosimilar monoclonal antibodies is driving the monoclonal antibody market's growth. The biosimilars' aim is to curb the increasing cost of healthcare and handle economic pressure from the patient pod and governments to reduce the cost of medication and increase access to treatment. Biosimilars are pharmaceuticals that are developed to have similar properties to a biological drug that has already been approved. A biosimilar monoclonal antibody costs 20%–25% less than the original biologic drug. The number of clinical trials for a biosimilar is comparatively smaller than that of the original biologic drug, and this proves to be the reason for the low cost of a biosimilar drug. In India, a new biosimilar policy called the ‘Guidelines on Similar Biologics’ prepared by the Central Drugs Standard Control Organization (CSDCO) is expected to give a major boost to the Indian biosimilar drugs industry. Alternative treatment methods and natural remedies are increasingly popular globally, and this is expected to hurt the revenues of the monoclonal antibody drugs market. Treatments in the fields of homeopathy, Ayurveda, yoga, acupuncture, and sujok therapy are gaining popularity and slowly replacing some traditional hospital practices. For instance, the revenue from US retail sales of homeopathic and herbal remedies was around $7.5 billion. These less expensive alternatives increase the competitiveness of the biologics market, putting downward pressure on prices and limiting the demand for monoclonal antibody drugs. The monoclonal antibody market has been witnessing multiple strategic initiatives in recent years. Top companies in the market are strategically acquiring start-ups and mid-sized companies to broaden their products and services. Strategic collaborations, acquisitions, and partnership agreements help vendors expand their existing product portfolio and geographical reach. For instance, in March 2022, Sanofi S.A., a France based pharmaceutical and healthcare company specialising in the discovery, development, manufacturing, and commercialization of drugs, announced a strategic collaboration with Seagen Inc., a US-based pharmaceutical company specialising in the development and commercialization of novel, powerful monoclonal antibody-based cancer treatments. Under this agreement, the partnership will use Seagen's and Sanofi's exclusive monoclonal antibody (mAb) and antibody-drug conjugate (ADC) technologies to design, develop, and market ADCs for up to three cancer targets. Furthermore, Boehringer Ingelheim, a Germany-based research-driven pharmaceutical company, announced a collaboration with MabGenesis, Inc., a Japan-based biopharmaceutical company pioneering in the development of therapeutic monoclonal antibody drugs for the treatment of human diseases. Through this collaboration, Boehringer Ingelheim and MabGenesis discover and develop novel therapeutic monoclonal antibodies for the treatment of various diseases and strategic research and development strategies. Companies in the industry are increasingly realigning their portfolios and pursuing profitable inorganic growth opportunities. Additionally, M&A interest is also being fueled by stronger corporate balance sheets, liquid debt markets, and continued favourable interest rates globally. The Food and Drug Administration (FDA) is a federal agency of the United States Department of Health and Human Services, in the USA, regulating the monoclonal antibody and pharmaceutical drug markets. Increasing product launches and regulatory support for the treatment of rare diseases by the USFDA are expected to support the monoclonal antibody therapeutics market's growth. For instance, the U.S. The Food and Drug Administration (FDA) granted accelerated approval to avelumab (BAVENCIO, EMD Serono, Inc.), a human monoclonal antibody, for the treatment of a rare disease, metastatic Merkel cell carcinoma (MCC). Similarly, the U.S. FDA granted accelerated approval to the immunotherapy product TECENTRIQ (atezolizumab), a humanized, engineered monoclonal antibody, for the treatment of people with locally-advanced or metastatic urothelial carcinoma (MUC). Major players in the monoclonal antibodies (MABS) market are Johnson & Johnson, Merck, AbbVie, Amgen, GlaxoSmithKline PLC., Norvatis AG, Pfizer Inc., Thermo Fisher Scientific, Eli Lilly and Company, and Bristol-Myers Squibb. North America was the largest region in the monoclonal antibodies (MAbS) market in 2022. The regions covered in the global monoclonal antibodies (MABS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the monoclonal antibodies (MABS) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The monoclonal antibodies (MABS) market consists of sales of rituximab, cetuximab, and trastuzumab. Values in this market are "factory gate values," that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global monoclonal antibodies (MABs) market is segmented - 1) By Source: Murine, Chimeric, Humanized, Human 2) By Application: Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies (MAbs), Neuropharmacological, Cardiovascular And Cerebrovascular, Other Applications 3) By End Users: Hospitals, Private Clinics, Research Institute

Drugs for immunotherapy refer to a kind of medication that offers treatment to either stimulate or suppress the immune system in order to aid the body's protection against cancer, infection, and other disorders. Your immune system is assisted in fighting cancer via immunotherapy, a sort of cancer treatment. The body's immune system aids in the fight against infections and other disorders. The main types of drugs for immunotherapy are monoclonal antibodies, interferons, interleukins, vaccines, checkpoint inhibitors, and others. Monoclonal antibodies are created by cloning a single white blood cell. Every subsequent antibody generated in this manner may be traced back to a single parent cell. The different areas of therapy include cancer, autoimmune and inflammatory diseases, infectious diseases, and others, and they are used by various sectors such as hospitals and clinics, ambulatory surgical centres, and others. The drugs for immunotherapy market research report is one of a series of new reports from The Business Research Company that provides drugs for immunotherapy market statistics, including drugs for immunotherapy industry global market size, regional shares, competitors with drugs for immunotherapy market share, detailed drugs for immunotherapy market segments, market trends and opportunities, and any further data you may need to thrive in the drugs for immunotherapy industry. This drug for immunotherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global drugs for immunotherapy market grew from $208.56 billion in 2022 to $231.12 billion in 2023 at a compound annual growth rate (CAGR) of 10.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The drugs for immunotherapy market is expected to grow from $349.53 billion in 2027 at a CAGR of 10.9%. The immunotherapy drugs market is being driven by rising incidences of cancer globally. The major causes of most cancers include obesity, smoking, alcohol, and improper eating habits. For instance, in February 2022, according to a report shared by the WHO, a Switzerland-based specialised agency of the United Nations responsible for international public health, roughly 10 million deaths, or nearly one in six deaths, will be caused by cancer in 2020, making it the top cause of death globally. Breast, lung, colon, rectum, and prostate cancers are the most prevalent types of cancer. The use of tobacco, having a high body mass index, drinking alcohol, eating few fruits and vegetables, and not exercising account for about one-third of cancer-related fatalities. The rising incidences of cancer are expected to increase the demand for immunotherapy drugs driving the market's growth. The high cost of immunotherapy drugs is acting as a restraint on the drugs for the immunotherapy market as a smaller number of patients can afford the treatment. Immunotherapy drugs are expensive as they are made specifically for each patient, and investment costs in the research and development are high. For instance, Novartis’ Kymriah and Gilead Sciences’ Yescarta are two immunotherapy treatments that cost between $373,000 and $475,000 per patient, depending on the type of cancer. The Yervoy (ipilimumab) drug from Bristol-Myers Squibb, for the treatment of melanoma, a type of skin cancer, costs $120,000 per course of treatment. The high cost of immunotherapy drugs makes them unaffordable, thereby affecting their market growth. Manufacturers of immunotherapy drugs are increasingly collaborating or partnering with other companies to share technology, resources, and product knowledge and expand the business. For example, Illumina Inc. and Bristol-Myers Squibb (BMS) collaborated to utilise Illumina’s next-generation sequencing (NGS) technology to develop and commercialize in-vitro diagnostic (IVD) assays in support of Bristol-Myers Squibb's oncology portfolio. Allogene Therapeutics Inc. and Pfizer Inc. entered into an asset contribution agreement to use Pfizer’s portfolio of assets related to allogeneic CAR-T therapy. Manufacturers of immunotherapy drugs are governed by various regulatory bodies, such as the Food and Drug Administration in the USA. The Food and Drug Administration (FDA) regulates drugs and biologics under the authority granted to it by the Federal Food, Drug, and Cosmetic Act (FD&C Act) and its amendments. Under this authority, FDA regulates the pre-market testing and marketing approval for all immunotherapeutic agents, either as drugs or biologics, depending on the source and function of the investigational agent. Immunotherapeutic products that are regulated as biologics include antibodies and proteins, and some nucleic acids. In August 2020, Bristol Myers Squibb, a US-based pharmaceutical company that manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders, acquired Dragonfly Therapeutics’ investigational immunotherapy program for $475 million. Through this acquisition, Bristol Myers Squibb will be granted Dragonfly’s extended half-life cytokine DF6002, a monovalent IL-12 immunoglobulin Fc. Dragonfly Therapeutics, Inc. is a US-based discovery-stage company developing drugs to stimulate immune responses against cancer. Major players in the drugs for immunotherapy market are F. Hoffmann-La Roche Ltd., Novartis AG, Amgen, Inc., AbbVie, Inc., and Merck & Co. Inc., GlaxoSmithKline, Eli Lilly and Company, Bristol-Myers Squibb, AstraZeneca PLC., Johnson & Johnson, and UbiVac. North America was the largest region in the immunotherapy market in 2022. The Middle East is expected to be the fastest growing region in the global drug for immunotherapy market during the forecast period. The regions covered in the global drugs for immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the drugs for immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, USA. The drugs for immunotherapy market consists of sales of cytokines, CAR T-cell therapy, and cancer treatment vaccines. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global drugs for immunotherapy market is segmented - 1) By Type: Monoclonal Antibodies, Interferons, Interleukins, Vaccines, Checkpoint Inhibitors, Other Types 2) By Therapy Area: Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases, Other Therapy Areas 3) By End User: Hospitals & Clinics, Ambulatory Surgical Centers, Other End Users

Antibody-drug conjugates (ADCs) refer to medications that are specifically designed to administer chemotherapy to cancer cells. ADCs deliver chemotherapy via a linker connected to a monoclonal antibody that binds to a specific target expressed on cancer cells.As soon as the ADC binds to its target (a cancer protein or receptor), a cytotoxic chemical is released into the cancer cell. The main types of antibody-drug conjugates are monoclonal antibodies, linkers, drugs or toxins, and others. Monoclonal antibodies are created by cloning a single white blood cell. Every subsequent antibody generated in this manner may be traced back to a single parent cell. The different products include Adcertis, Kadcyla, and others and involve various technologies such as immunogen technology, Seattle genetics technology, immunomedics technology, and others. It is used in blood cancer, breast cancer, ovarian cancer, lung cancer, brain tumours, and others, and is implemented in hospitals, clinics, and others. The antibody-drug conjugates (ADCs) market research report is one of a series of new reports from The Business Research Company that provides antibody-drug conjugates (ADCs) market statistics, including antibody-drug conjugates (ADCs) industry global market size, regional shares, competitors with an antibody-drug conjugates (ADCs) market share, detailed antibody-drug conjugates (ADCs) market segments, market trends and opportunities, and any further data you may need to thrive in the antibody-drug conjugates (ADCs) industry. This antibody-drug conjugates (ADCs) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.. The global antibody drug conjugates market grew from $5.9 billion in 2022 to $7.2 billion in 2023 at a compound annual growth rate (CAGR) of 22.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The antibody drug conjugates market is expected to grow from $16.15 billion in 2027 at a CAGR of 22.4%. The antibody-drug conjugates market is being driven by rising incidences of cancer globally. The major causes of most cancers include obesity, smoking, alcohol, and improper eating habits. Cancer Research UK predicts that there will be 27.5 million new cases of cancer each year by 2040. The rising incidences of cancer are expected to increase the demand for antibody-drug conjugates, driving the market's growth. The challenges involved in the manufacturing of ADCs is acting as a restraint on the antibody drug conjugates market. ADC manufacturing facilities necessitate a significant capital investment as well as extensive specialised training for operators. ADC process development is complicated as it requires optimization of additional process steps that are not present in conventional monoclonal antibody manufacturing, such as the antibody-drug conjugation reaction and subsequent drug substance purification. Also, antibody-drug conjugates must be manufactured in aseptic environments, and operating personnel should be protected from the highly toxic drug compounds, thereby presenting operational difficulties. Manufacturers of antibody-drug conjugates are increasingly collaborating or partnering with other companies to share technology, resources, and product knowledge and expand the business. For instance, in March 2022, Sanofi, a France-based multinational pharmaceutical and healthcare company, collaborated with a US-based biotechnology company, Seagen Inc., to create up to three cancer targets for antibody-drug conjugates (ADCs), develop them, and market them. The collaboration would make use of the exclusive monoclonal antibody (mAb) technology from Sanofi and the exclusive ADC technology from Seagen. Through this cooperation, candidate medications with the potential to give cancer patients and their families fresh hope would be created via the synergistic combination of molecules and platforms. Manufacturers of antibody-drug conjugates are monitored by various regulatory bodies, such as the Food and Drug Administration in the USA. In the USA, there is no specific regulatory guidance for the industry on ADC development, and the FDA follows existing guidelines for small drugs and monoclonal antibodies to regulate ADC. The product quality offices at the FDA, such as the Office of Biotechnology Products (OBP) and Office of Pharmaceutical Quality, primarily focus on the manufacturing of the antibody component of the ADC and the control strategy for the antibody intermediate, as well as for the drug substance (DS) and drug product (DP). The small molecule review groups in the Office of Pharmaceutical Quality bear primary responsibility for the review of the adequacy of the payload and linker, conjugation reactions, and aspects of the control strategy. Major players in the antibody-drug conjugates (ADCs) market are Bayer AG, Concortis Biotherapeutics, F. Hoffmann-La Roche Ltd., Immunomedics Inc., Oxford BioTherapeutics, Pfizer Inc., Seattle Genetics Inc., Takeda Pharmaceutical Company Limited, Abbvie Inc., and Astellas Pharma/Agensys. North America was the largest region in the antibody-drug conjugates (ADCs) market in 2022. The Middle East is expected to be the fastest growing region in the global antibody drug conjugates market during the forecast period. The regions covered in the global antibody-drug conjugates (ADCs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the antibody-drug conjugates (ADCs) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The antibody-drug conjugates (ADCs) market consists of sales of enfortumab vedotin, sacituzumab govitecan, trastuzumab emtansine, and trastuzumab deruxtecan. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global antibody drug conjugates market is segmented - 1) By Type: Monoclonal Antibodies, Linker, Drug/Toxin, Other Types 2) By Application: Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor, Other Applications 3) By Product: Adcertis, Kadcyla, Other Products 4) By Technology: Immunogen Technology, Seattle Genetics Technology, Immunomedics Technology, Other Technology 5) By End User: Hospital, Clinics, Other End Users

Autoimmune diseases diagnosis are the diseases in which the production of antibodies takes place in the body which attacks and destroys own healthy cells in the body. These include Crohn's disease, rheumatoid arthritis, Hashimoto’s disease, multiple sclerosis, Grave’s disease, psoriasis, coeliac disease, type 1 diabetes, lupus and inflammatory bowel syndrome, and are diagnosed by immunological tests. The main test types of autoimmune disease diagnosis are routine laboratory tests, autoantibodies tests, immunologic tests, and other tests. Autoantibody tests are used to aid in the diagnosis of autoimmune diseases. The different products include consumables and assay kits, instruments and are used by various sectors such as clinical laboratories, hospitals, and others. The autoimmune disease diagnosis market research report is one of a series of new reports from The Business Research Company that provides autoimmune disease diagnosis market statistics, including autoimmune disease diagnosis industry global market size, regional shares, competitors with a autoimmune disease diagnosis market share, detailed autoimmune disease diagnosis market segments, market trends and opportunities, and any further data you may need to thrive in the autoimmune disease diagnosis industry. This autoimmune disease diagnosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global autoimmune disease diagnosis market size will grow from $5.15 billion in 2022 to $5.56 billion in 2023 at a compound annual growth rate (CAGR) of 7.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global autoimmune disease diagnosis market size is expected to grow to $7.55 billion in 2027 at a CAGR of 8.0%. A high incidence of autoimmune diseases contributed to the growth of the autoimmune disease diagnosis market. According to the Autoimmune Registry Inc. (ARI) first comprehensive list of Autoimmune Diseases published in 2020, between 15 and 30 million people in the United States suffer from autoimmune disease, making it the nation's largest class of illness, and it primarily affects women aged 20 to 40. Therefore, increasing incidence of autoimmune diseases across the globe is driving the autoimmune disease diagnosis market. The high cost of diagnostic tests is a major challenge for the growth of the autoimmune disease diagnosis market. According to a survey by the National Adrenal Diseases Foundation (NADF), the cost for initial diagnosis of Addison’s disease is $1,680 per patient and according to the reports of Vasculitis Foundation of America, vasculitis affects 1 in 20 Americans and the total cost for vasculitis patient per year is $9.7 billion. According to the estimations of The National Institutes of Allergy and Infectious Diseases (NIAID), the annual cost of treating an autoimmune disease in the US is greater than $100 billion and says that annual direct and indirect cost to treat rheumatoid arthritis in the US is $10.9 billion and $8.4 billion respectively. The high cost of diagnosis is increasing the cost burdens on the patients impacting the growth of the autoimmune disease diagnosis market Biosensors and nano biosensors for rapid detection is a novel tool for the detection of antibodies in the autoimmune disease diagnosis market. They are highly preferred because of low cost, high sensitivity, simple to use, multiplexing abilities and rapid diagnosis. Besides measuring the quantity of antibodies in human blood serum with extremely high sensitivity, it also quantifies the activity of antibodies as the assay employs portable optical label-free biosensors based on the spectral correlation interferometry. This point of care technology gives a more integrated, informative, timely and precise diagnosis of autoimmune diseases when compared to the conventional ones. Major players in the autoimmune disease diagnosis market are Thermo Fisher Scientific, Siemens Healthineers, Abbott, Danaher, Bio-Rad Laboratories, Trinity Biotech, HYCOR Biomedical, EUROIMMUN AG, AESKU GROUP GMBH & CO. KG and F. Hoffmann-La Roche Ltd. North America was the largest region in the autoimmune disease diagnosis market in 2022. Western Europe was the second largest region in the global autoimmune disease diagnosis market. The regions covered in the global autoimmune disease diagnosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the autoimmune disease diagnosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The autoimmune disease diagnosis market includes revenue earned by diagnostic assay kits, reagents, consumables and instruments used for the diagnosis of autoimmune diseases. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global autoimmune disease diagnosis market is segmented - 1) By Product: Consumables & Assay Kits, Instruments 2) By Test Type: Routine Laboratory Tests, Autoantibodies Tests, Immunologic Tests, Other Tests 3) By End User: Clinical Laboratories, Hospitals, Other End Users

Biosimilar monoclonal antibodies refer to a member of the family of biosimilars. Large, intricate proteins are typically given as part of the treatment for conditions like cancer or rheumatoid arthritis. They are employed by the immune system to recognise and destroy foreign substances, including bacteria, viruses, and others. The main types of biosimilar monoclonal antibodies are synthetic chemicals, biopharmaceuticals, and others. Any pharmaceutical drug product made from, derived from, or semi-synthesized from biological sources is known as a "biopharmaceutical," sometimes known as a "biologic medical product," or "biologic. The different compounds include infliximab, rituximab, abciximab, trastuzumab, adalimumab, and bevacizumab and are used in various applications such as chronic and autoimmune diseases, oncology, and others. The biosimilar monoclonal antibodies market research report is one of a series of new reports from The Business Research Company that provides biosimilar monoclonal antibodies market statistics, including industry global market size, regional shares, competitors with a biosimilar monoclonal antibodies market share, detailed biosimilar monoclonal antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the biosimilar monoclonal antibodies industry. This biosimilar monoclonal antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global biosimilar monoclonal antibodies market grew from $5.47 billion in 2022 to $6.63 billion in 2023 at a compound annual growth rate (CAGR) of 21.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The biosimilar monoclonal antibodies market is expected to grow from $11.29 billion in 2027 at a CAGR of 14.3%. The prevalence of chronic diseases is expected to drive the biosimilar monoclonal antibodies market. Biosimilar monoclonal antibodies are used to treat chronic diseases such as cancer, autoimmune disease, and rheumatoid arthritis. In cancer treatment, biosimilars of monoclonal antibodies such as trastuzumab, bevacizumab, and rituximab are used. Moreover, the incidence of cancer is increasing year by year. According to the American Cancer Society (ACS), in 2020, about 1.8 million new cancer cases are expected in the United States. Therefore, the prevalence of chronic diseases, including cancer, is expected to drive the biosimilar monoclonal antibodies market. Stringent regulations imposed on approvals of biosimilars are anticipated to hinder the growth of the biosimilar monoclonal antibody market. The governments of different regions impose different rules regarding the production and use of biosimilars. Further, issues such as patent infringement or agreement issues restrict the manufacturers of biosimilars from commercialising the government-approved biosimilars. The US Food and Drug Administration requires double regulatory approval for biosimilars, restricting the use of biosimilars as interchangeable drugs for biologics, whereas, in Europe, the European Medicines Agency (EMA) approves biosimilars as interchangeable products for biologics. In February 2019, out of the total 17 approved biosimilars, only 7 biosimilars, including 4 originating biologics, could enter the US commercial market. The strict government policies for approval of these drugs negatively impact manufacturers in the biosimilar monoclonal antibody market. The focus areas for many companies in the biosimilar monoclonal antibody market have shifted to mergers and acquisitions to acquire more production capabilities. Large prime manufacturers are forming joint ventures or buying small or midsized companies to acquire new capabilities, or to gain access to new markets. For instance, Aurobindo Pharma Limited acquired four cell culture-derived biosimilar products from TL Biopharmaceutical AG of Switzerland. As part of the agreement, TL will supply all the developmental data for four molecules, and Aurobindo and/or its affiliates will develop, commercialize, and market these products globally. Out of the four biosimilars acquired, three of them are monoclonal antibodies in oncology. In another case, in May 2020, AbbVie, a biopharmaceutical company based in the United States, announced its intention to acquire Allergan for $63 million.This transaction expands and diversifies AbbVie's revenue base and supports in maintaining its leadership position in biosimilar monoclonal antibodies. In May 2020, AbbVie, a US-based biopharmaceutical company, acquired Allergan for an amount of $63 million. This transaction expands and diversifies AbbVie's revenue base and supports maintaining its leadership position in biosimilar monoclonal antibodies. Allergan is an Ireland-based pharmaceutical company that manufactures, develops, and markets drugs, biosimilars, medical devices, eye care, and others. Major players in the biosimilar monoclonal antibodies market are Pfizer, Novartis, Allergan, Coherus BioSciences, Biocon, Amgen, Boehringer Ingelheim, Celltrion, BioXpress Therapeutics, and Intas Pharmaceuticals Limited. North America was the largest region in the biosimilar monoclonal antibodies market in 2022. The regions covered in the global biosimilar monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the biosimilar monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The biosimilar monoclonal antibodies market consists of sales of Blitzima, Ritemvia, Rituzena, and Truxima. Values in this market are "factory gate values," that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global biosimilar monoclonal antibodies market is segmented - 1) By Type: Synthetic Chemicals, Biopharmaceuticals, Other Types 2) By Application: Chronic & Autoimmune Diseases, Oncology, Other Applications 3) By Compound: Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab

Protein labelling refers to the process of detecting or purifying the labelled protein and its binding partners by using the proper molecular labels. Most biological research uses one of three basic categories of protein labels: biotin, enzyme conjugates, or fluorescence probes. The main types of products in protein labelling are reagents, proteins, enzymes, probes or tags, and monoclonal antibodies. Monoclonal antibodies are created by cloning a single white blood cell. Every subsequent antibody generated in this manner may be traced back to a single parent cell. The different labelling methods include in-vitro labeling, and in-vivo labelling and are used in cell-based assays, fluorescence microscopy, immunological techniques, mass spectrometry, and protein microassays. The protein labelling market research report is one of a series of new reports from The Business Research Company that provides protein labelling market statistics, including the industry's global market size, regional shares, competitors with a protein labelling market share, detailed protein labelling market segments, market trends and opportunities, and any further data you may need to thrive in the protein labelling industry. This protein labelling market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global protein labelling market grew from $2.13 billion in 2022 to $2.35 billion in 2023 at a compound annual growth rate (CAGR) of 10.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The protein labelling market is expected to grow from $3.49 billion in 2027 at a CAGR of 10.4%. Increased spending on the R&D of proteomics and genomics is driving the growth of the protein labelling reagents market. Proteomics is the study of the overall protein content of a cell, tissue, or organism. Protein labelling methods before separation and analysis are essential during proteomic profiling approaches. For instance, the National Institutes of Health (NIH) of the United States, funded $37 billion for biomedical research. This funding is for life sciences research that supports study at a molecular level for the understanding of fundamental processes by which diseases develop, the identification of biomarkers that signal the presence of disease, or identification of genes or proteins responsible for the disease. The Novo Nordisk Foundation granted a grant of up to $1.5 million to the University of Copenhagen to establish a mass spectrometry facility, which marks a new and exciting step in protein research. Therefore, the increased spending on research and development of proteomics and genomics is driving the market. Drawbacks related to protein labelling techniques are expected to hinder the market. Label-free techniques are preferred over labelled techniques because of the drawbacks associated with them, such as wet-lab complexity and flexibility. While label-free samples can be measured without much preparation, wet lab pre-treatment is required for all labelling techniques. Samples must be labelled with metabolic (e.g. SILAC) or chemical (e.g. iTRAQ or TMT) reagents and the different conditions has to be combined. Therefore, label-free techniques are less prone to wet lab errors than labelling techniques. Label-free approaches have the advantage of being highly adaptable, even after the study has begun. New samples can be included at any time, but labelled approaches require the same number (n) of each condition. New samples may not be included in the study if they cannot be physically mixed and measured with the control. Labeled techniques such as the Super-SILAC approach reduce this problem but must also be carefully planned. These disadvantages are making label-free techniques preferable. Therefore, drawbacks associated with protein labeling techniques are expected to hinder the market. Companies in the protein labelling market are increasing their product innovation through strategic collaborations. To sustain in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated as well as academic and research institutions in this market by way of partnerships, in or out-licensing deals, this trend has been increasing over recent years. For instance, recombinant protein manufacturer enGenes Biotech GmbH (enGenes) announced a collaboration with ACIB GmbH for protein labeling. In January 2020, Abcam, a UK-based protein research tools producer and seller, announced its decision to acquire Expedeon's Proteomics and Immunology business, which includes Innova and TGR Biosciences. Expedeon technology supports a diverse set of labels, including enzymes, metals, oligos, and fluorescent proteins. Abcam will combine the newly acquired capture and conjugation technologies with its extensive antibody and protein expertise to expand and enhance its portfolio of off-the-shelf, and custom reagents and tools. Expedeon is a Germany-based manufacturer of protein discovery and analysis products used for protein and drug research. Major players in the protein labelling market are Thermo Fisher Scientific Inc., Merck KGaA, PerkinElmer, Inc., General Electric Company, F. Hoffmann-La Roche AG, AGILENT TECHNOLOGIES INC., BIO-RAD LABORATORIES, Kirkegaard & Perry Laboratories, LI-COR Inc. and Kaneka Corporation. North America was the largest region in the protein labeling market in 2022. The regions covered in the global protein labelling market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the protein labelling market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The protein labeling market includes revenues earned by entities by detecting or purifying the labelled protein and its binding partners. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global protein labelling market is segmented - 1) By Product: Reagents, Protein, Enzymes, Probes/ Tags, Monoclonal Antibodies 2) By Labeling Method: In-vitro Labeling, In-vivo Labeling 3) By Application: Cell Based-Assay, Fluorescence Microscopy, Immunological Techniques, Mass Spectrometry, Protein Micro Assay

Conjugated monoclonal antibodies refer to a compound formed from a monoclonal antibody that has been chemically coupled to a medication. The monoclonal antibody binds to particular proteins or receptors that are present on particular cell types, such as cancer cells. The associated medicine enters these cells, kills them, and leaves the rest of the cells alone. The main types of drugs in conjugated monoclonal antibodies are advertised and kadcyla. Adcetris is a brand-name pharmaceutical drug intended to cure adults with certain types of lymphoma. Lymphoma is a cancer that attacks the lymphatic system and lymphocytes, which are white blood cells. The different technologies include cleavable linkers and non-cleavable linkers and are used in blood cancer, breast cancer, ovarian cancer, lung cancer, brain tumours, and others. The conjugated monoclonal antibodies market research report is one of a series of new reports from The Business Research Company that provides conjugated monoclonal antibodies market statistics, including industry global market size, regional shares, competitors with a conjugated monoclonal antibodies market share, detailed conjugated monoclonal antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the conjugated monoclonal antibodies industry. The conjugated monoclonal antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global conjugated monoclonal antibodies market grew from $9.64 billion in 2022 to $10.3 billion in 2023 at a compound annual growth rate (CAGR) of 6.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The conjugated monoclonal antibodies market is expected to grow from $12.86 billion in 2027 at a CAGR of 5.7%. The increasing popularity and therapeutic potential of conjugated monoclonal antibodies, especially antibody-drug conjugates, is expected to drive the conjugated monoclonal antibodies market over the forecast period. Antibody-drug conjugates (ADCs), a class of therapeutics consisting of monoclonal antibodies (MAbs) clubbed with highly potent cytotoxic drugs through a linker to kill the antigen-expressing tumour cells, are predominantly used in the treatment of cancer. In the last three to four years, the U.S. Food and Drug Administration has approved only three antibody-drug conjugates, indicating that the increased number of approvals is directly proportional to the use of conjugated monoclonal antibodies, mainly in the field of cancer, which in turn aids in the growth of the market. The high cost of conjugated monoclonal antibodies is anticipated to limit the growth of the conjugated monoclonal antibodies market. For instance, the first FDA-approved radioimmunotherapy drug, Yttrium 90 Ibritumomab Tiuxetan Therapeutic (Zevalin), is priced at around $55,000. Moreover, Padcev, an antibody-drug conjugate from Seattle Genetics and Astellas that was approved in December 2019, costs between $110,000 to $120,000 for a course of treatment. The high cost of the therapy makes it unaffordable for the patients and healthcare systems of underdeveloped countries, which hinders the growth of the conjugated monoclonal antibody market. Companies operating in the conjugated monoclonal antibodies market are focusing on strategic collaborations and partnerships for developing new conjugated monoclonal antibodies and shaping the market. For instance, in June 2020, Monopar Therapeutics, a USA-based biopharmaceutical company, and NorthStar Medical Radioisotopes entered in collaboration to couple Monopar’s MNPR-101, a humanised urokinase plasminogen activator receptor (uPAR) targeted monoclonal antibody in pre-IND stage, to a therapeutic radioisotope of NorthStar to create a highly selective agent, that has the potential to kill aberrantly activated cytokine-producing immune cells. AstraZeneca, a UK-based pharmaceutical company, announced a $6 billion partnership with Daiichi Sankyo in July 2020.This deal is for the global development and commercialization of DS-1062, a TROP2-targeted antibody-drug conjugate (ADC), which is a type of drug that works by using a monoclonal antibody to deliver an attached pharmaceutical payload directly to tumour cells. Daiichi Sankyo is a Japanese-based pharmaceutical company engaged in the development of antibody-drug conjugates. Major players in the conjugated monoclonal antibodies market are Pfizer Inc., F. Hoffmann-La Roche, Bristol-Myers Squibb, and Merck & Co. Inc., Immunomedics Inc., Takeda Pharmaceuticals Industries Ltd., Daiichi Sankyo Company Limited, Actinium Pharmaceutical, Nordic Nanovector Inc., and Spectrum Pharmaceuticals Inc. North America was the largest region in the conjugated monoclonal antibody market in 2022. The Middle East is expected to be the fastest growing region in the global conjugated monoclonal antibodies market during the forecast period. The regions covered in the global conjugated monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the conjugated monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The conjugated monoclonal antibodies market consists of sales of Brentuximab vedotin and Ado-trastuzumab emtansine. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global conjugated monoclonal antibodies market is segmented - 1) By Drugs: Adcetris, Kadcyla 2) By Technology: Cleavable Linker, Non-cleavable Linker 3) By Application: Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumour, Other Applications

Arthritis monoclonal antibodies refer to a class of sophisticated and useful biologic medicines used to treat rheumatoid arthritis and other immune-mediated inflammatory conditions. They inhibit the inflammatory protein interleukin-6, which reduces arthritis-related joint pain and swelling as well as other inflammation-related symptoms. In order to prevent the body from rejecting the new organ after surgery, they reduce the body's defence mechanism. The main types of drugs in arthritis monoclonal antibodies are remicade, humira, enbrel, rituxan, orencia, actemra, simponi, cimzia, and remsima. REMICADE is a prescription drug for persons with slightly too severely active Crohn's disease who haven't had success with other treatments. The different applications include rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ankylosing spondylitis, fibromyalgia, and others and involve various sectors such as hospitals, research institutes, and others. The arthritis monoclonal antibodies market research report is one of a series of new reports from The Business Research Company that provides arthritis monoclonal antibodies market statistics, including arthritis monoclonal antibodies industry global market size, regional shares, competitors with arthritis monoclonal antibodies market share, detailed arthritis monoclonal antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the arthritis monoclonal antibodies industry. This arthritis monoclonal antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global arthritis monoclonal antibodies market grew from $49.44 billion in 2022 to $53.81 billion in 2023 at a compound annual growth rate (CAGR) of 8.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The arthritis monoclonal antibodies market is expected to grow from $71.66 billion in 2027 at a CAGR of 7.4%. The increasing prevalence of arthritis globally has contributed to the growth of the arthritis monoclonal antibody market. According to the Centre for Disease Control and Prevention (CDC), in 2020, the adult percentage of arthritis is 23% in the USA which varies by country and osteoarthritis is the most common form of arthritis followed by gout, fibromyalgia, and rheumatoid arthritis. According to WHO, the prevalence of rheumatoid arthritis varies between 0.3% and 1%, and the worldwide estimates of osteoarthritis include 9.6% of men and 18% of women. The increased prevalence of arthritis and the demand for personalized medicine are increasing the demand for the arthritis monoclonal antibody market. The high cost of monoclonal antibodies is expected to hamper the global arthritis monoclonal antibody market. According to the American Journal of Managed Care (AJMC), a survey was conducted to know the average price of monoclonal antibodies approved in the last 20 years by the FDA across disease states and found that the average annual price of 1-year treatment for each monoclonal antibody indication was $96,731. The high costs of these antibodies are basically due to the cost incurred in development and production. High costs of monoclonal antibodies are therefore expected to limit the market growth. The development of therapeutic monoclonal antibody products is becoming an indispensable tool in the development of the arthritis monoclonal antibody market. Monoclonal antibodies are more efficient than small molecules and peptides in the treatment of arthritis. These are target specific and have good efficiency for disease treatment. These improved treatment options are evident with the launch of a greater number of monoclonal antibody drugs for arthritis. In May 2020, AbbVie acquired Allergan for $63 billion. AbbVie is a global biopharmaceutical company whose key therapeutic areas include Immunology and Neuroscience. It is now significantly expanding its revenue base and maintaining its position in immunology by acquiring Allergan. Allergan is a global pharmaceutical leader that manufactures devices, biologics, and surgical and regenerative medicinal products all across the world. Major players in the arthritis monoclonal antibody market are Johnson & Johnson, Roche, Novartis, Pfizer Inc., AbbVie Inc., Amgen Inc., Genentech, GSK, AstraZeneca PLC., and Mylan N.V. North America was the largest region in the arthritis monoclonal antibodies market in 2022. The regions covered in the global arthritis monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the arthritis monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The arthritis monoclonal antibodies market consists of sales of infliximab, adalimumab, golimumab, and certolizumab. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global arthritis monoclonal antibody market is segmented - 1) By Drug: Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, Remsima 2) By Application: Rheumatoid Arthritis, Osteoarthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Fibromyalgia, Other Applications 3) By End-Use: Hopitals, Research Institutes, Other End-Users